Biopharma prepares to pivot from China as Biosecure Act advances

Some of the most widely used CROs and CDMOs among U.S. pharma and biotech companies are based in China. But the industry may soon be forced to cut ties with these partners if the Biosecure Act, which was passed in the House last week, is ultimately signed into law.